Rising Number of CAR T-Cell Therapies in Clinical Trials Fuels the Middle East & Africa T Cell Therapy Market
The current landscape for CAR T-cell therapies across the globe is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain.
In November 2022, Peter MacCallum Cancer Centre and Cartherics Pty Ltd entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR T cell therapy (CTH-001) for treating cutaneous T-cell lymphoma (CTCL). The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. It will initially enroll six patients with refractory CTCL.
JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL.
Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL).
ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
Descartes-11, a mRNA CAR T-cell therapy, has moved into a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. Descartes-11 expresses CAR T-cell molecules transiently and avoids some characteristic toxicities of these therapeutic agents. A Phase I study (NCT03994705) of 18 patients has already been undertaken, and results showed no evidence of cytokine release syndrome or neurotoxicity—adverse events commonly associated with CAR T-cell treatment.
Thus, the pipelines above for CAR T-cell therapies are emerging as a new trend in the Middle East & Africa T-cell therapy market.
Middle East & Africa T Cell Therapy Market Overview
The T-cell therapy market in the Middle East & Africa is segmented into Israel, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The T-cell therapy market in the Middle East & Africa is anticipated to grow due to the approval of CAR T-cell therapies and increasing healthcare expenditure. In September 2022, Gilead and Kite established a fully functional cell therapy business unit after the regulatory approval of T-cell therapies such as Yescarta and Tecartus. T-cell therapies will soon be available for the Saudi Arabian population. According to an article published by the National Library of Medicine, CAR T-cell therapy is not yet approved in the UAE; however, it is expected to be approved within the next 2 years.
Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Middle East & Africa T Cell Therapy Market Segmentation
The Middle East & Africa T cell therapy market is segmented into modality , therapy type, indication, and country.
Based on modality, the Middle East & Africa T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.
Based on therapy type, the Middle East & Africa T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.
Based on indication, the Middle East & Africa T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.
Based on country, the Middle East & Africa T cell therapy market is segmented into Saudi Arabia, Israel, and Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa T cell therapy market in 2022.
Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Middle East & Africa T cell therapy market.
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa T cell therapy market
Highlights key in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa T cell therapy market , thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
- 1. Introduction
- 1.1 The Insight Partners Research Report Guidance9
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 2.2 Middle East & Africa T Cell Therapy Market, by Country (US$ Million)
- 3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
- 4. Middle East & Africa T Cell Therapy Market Landscape
- 4.1 Overview
- 5. Middle East & Africa T Cell Therapy Market - Key Industry Dynamics
- 5.1 Market Drivers:
- 5.1.1 Growing Burden of Cancer Worldwide
- 5.1.2 Increasing Number of T-Cell Therapy Approvals
- 5.2 Market Restraints
- 5.2.1 Side-effects of CAR T-Cell Therapy
- 5.3 Market Opportunities
- 5.3.1 Growing Investment in T-Cell Therapy
- 5.4 Future Trends
- 5.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
- 5.5 Impact Analysis:
- 6. T Cell Therapy Market - Middle East & Africa Market Analysis
- 6.1 Middle East & Africa T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
- 7. Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality
- 7.1 Overview
- 7.2 Middle East & Africa T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
- 7.3 Research
- 7.3.1 Overview
- 7.3.2 Research: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4 Commercialized
- 7.4.1 Overview
- 7.4.2 Commercialized: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 8. Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type
- 8.1 Overview
- 8.2 Middle East & Africa T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
- 8.3 CAR T-cell Therapy
- 8.3.1 Overview
- 8.3.2 CAR T-cell Therapy: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 8.4 T-cell Receptor (TCR)-based.
- 8.4.1 Overview
- 8.4.2 T-cell Receptor (TCR)-based: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 9. Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication
- 9.1 Overview
- 9.2 Middle East & Africa T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
- 9.3 Hematologic Malignancies
- 9.3.1 Overview
- 9.3.2 Hematologic Malignancies: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.3 Middle East & Africa T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
- 9.4 Solid Tumor
- 9.4.1 Overview
- 9.4.2 Solid Tumor: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 10. Middle East & Africa T Cell Therapy Market - Country Analysis
- 10.1 Overview
- 10.1.1.1 Middle East & Africa T Cell Therapy Market, by Country
- 10.1.1.2 Saudi Arabia
- 10.1.1.2.1 Saudi Arabia: Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.1.2.2 Saudi Arabia: Middle East & Africa T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.1.1.2.3 Saudi Arabia: Middle East & Africa T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.1.1.2.4 Saudi Arabia: Middle East & Africa T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
- 10.1.1.2.4.1 Saudi Arabia: Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
- 10.1.1.3 Israel
- 10.1.1.3.1 Israel: Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.1.3.2 Israel: Middle East & Africa T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.1.1.3.3 Israel: Middle East & Africa T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.1.1.3.4 Israel: Middle East & Africa T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
- 10.1.1.3.4.1 Israel: Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
- 10.1.1.4 Rest of Middle East & Africa
- 10.1.1.4.1 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.1.4.2 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.1.1.4.3 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.1.1.4.4 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
- 10.1.1.4.4.1 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
- 11. T Cell Therapy Market-Industry Landscape
- 11.1 Overview
- 11.2 Growth Strategies in T Cell Therapy Market
- 11.3 Organic Growth Strategies
- 11.3.1 Overview
- 11.4 Inorganic Growth Strategies
- 11.4.1 Overview
- 12. Company Profiles
- 12.1 Legend Biotech Corp
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 Janssen Global Services LLC
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 Gilead Sciences Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 Bristol-Myers Squibb Co
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Novartis AG
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 13. Appendix
- 13.1 About Us
- 13.2 Glossary of Terms
- LIST OF TABLES
- Table 1. Middle East & Africa T Cell Therapy Market Segmentation
- Table 2. Middle East & Africa T Cell Therapy Market, by Hematological Malignancies - Revenue and Forecast to 2030 (US$ Million)
- Table 3. Saudi Arabia: Middle East & Africa T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
- Table 4. Saudi Arabia: Middle East & Africa T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
- Table 5. Saudi Arabia: Middle East & Africa T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
- Table 6. Saudi Arabia: Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
- Table 7. Israel: Middle East & Africa T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
- Table 8. Israel: Middle East & Africa T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
- Table 9. Israel: Middle East & Africa T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
- Table 10. Israel: Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
- Table 11. Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
- Table 12. Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
- Table 13. Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
- Table 14. Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
- Table 15. Recent Organic Growth Strategies in T Cell Therapy Market
- Table 16. Recent Inorganic Growth Strategies in the T Cell Therapy Market
- Table 17. Glossary of Terms, Middle East & Africa T Cell Therapy Market
- LIST OF FIGURES
- Figure 1. Middle East & Africa T Cell Therapy Market Segmentation, By Country
- Figure 2. Middle East & Africa T Cell Therapy Market - Key Industry Dynamics
- Figure 3. Impact Analysis of Drivers and Restraints
- Figure 4. Middle East & Africa T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
- Figure 5. Middle East & Africa T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
- Figure 6. Research: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- Figure 7. Commercialized: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- Figure 8. Middle East & Africa T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
- Figure 9. CAR T-cell Therapy: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- Figure 10. T-cell Receptor (TCR)-based: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- Figure 11. Middle East & Africa T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
- Figure 12. Hematologic Malignancies: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- Figure 13. Solid Tumor: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- Figure 14. Middle East & Africa T Cell Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
- Figure 15. Middle East & Africa T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
- Figure 16. Saudi Arabia: Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- Figure 17. Israel: Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- Figure 18. Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- Figure 19. Growth Strategies in T Cell Therapy Market
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook